Vasomedical Turns To Angina Market Following Negative CMS Decision
This article was originally published in The Gray Sheet
Executive Summary
Vasomedical is counting on a two-pronged strategy of increasing Luminair EECP external counterpulsation therapy sales for angina treatment and decreasing expenses to stay afloat following a detrimental CMS proposed decision